ESC 365 - DANFLU-2: High-Dose vs. Standard-Dose Influenza Vaccine and Cardio-Respiratory Outcomes in Older Adults

ESC Professional Premium Access

DANFLU-2: High-Dose vs. Standard-Dose Influenza Vaccine and Cardio-Respiratory Outcomes in Older Adults

Session: Late-Breaking Clinical Trials: vaccinations in cardiovascular prevention

Topic: Public Health

Speaker: Professor T. Biering-Sorensen (Copenhagen, DK)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Professor Tor Biering-Sorensen

Gentofte University Hospital, Copenhagen (Denmark)

18 presentations

1 follower

4 more presentations in this session

KP-VACCINATE: Cardiovascular Focused Messaging for Influenza Vaccination

Speaker: Doctor A. Bhatt (San Francisco, US)

DAN-RSV: RSVpreF vaccine for preventing cardiorespiratory hospitalizations

Speaker: Professor T. Biering-Sorensen (Copenhagen, DK)

Population Assessment of Influenza and Disease Activities

Speaker: Doctor X. Du (Beijing, CN)

Impact of a pneumococcal vaccination incentive campaign

Speaker: Professor F. Roubille (Montpellier, FR)

Access the full session

Late-Breaking Clinical Trials: vaccinations in cardiovascular prevention

Speakers: Professor T. Biering-Sorensen, Doctor A. Bhatt, Professor T. Biering-Sorensen, Doctor X. Du, Professor F. Roubille

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources